Sention Therapeutics, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism

Phase 2

Completed

Conditions: Hypothyroidism

Interventions: Drug: ST-1891
Drug: Levothyroxine

First Posted Date: 2022-06-09

Last Posted Date: 2024-08-26

Lead Sponsor: Sention Therapeutics, LLC

Target Recruit Count: 490

Registration Number: NCT05412979

Locations: 🇺🇸
Sention Investigational Site, Renton, Washington, United States

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy